吡格列酮对2型糖尿病疗效和血脂影响的研究

Therapeutic Effect of Pioglitazone on the Treatment of Type II Diabetes and Blood Lipid Level

目的观察联合吡格列酮治疗2型糖尿病的疗效和对血脂的影响。方法240例2型糖尿病患者随机分为两组,吡格列酮组(130例)在原治疗方案基础上联合吡格列酮30m g/d,对照组(110例)维持原治疗方案,疗程3个月,观察治疗前后患者空腹血糖、H bAlc、空腹胰岛素、稳态模式胰岛素抵抗指数(H OM A-IR)和血脂的变化。结果吡格列酮组空腹血糖、H bAlc、空腹胰岛素和H OM A-IR治疗后均较治疗前明显下降,分别下降了(1.7±1.8)m m ol/L,(1.1±1.1)%,(2.2±9.4)m U/L和(0.14±0.31),P均<0.05;而对照组治疗前后的变化则无明显差异(P均>0.05);吡格列酮组的甘油三酯(TG)、低密度脂蛋白(LDL-C)、总胆固醇(T-chol)都有明显下降和改善(P均<0.01)。结论吡格列酮可明显降低2型糖尿病患者的胰岛素水平,改善胰岛素抵抗,并能改善糖代谢、脂代谢紊乱。

Objective To study the therapeutic effect of pioglitazone on the treatment of type Ⅱ diabetes（T2DM） and blood lipid level.Method 240 T2DM patients were randomly divided into two groups, 110 in control group, 130 in treatment group. In the control group, patients were treated with standard protocol, while patients in treatment group were with standard protocol and together with pioglitazone 30mg/d for three months. Fasting blood glucose, HbAle, fasting insulin and HOMA-IR levels were monitored. Results The fasting blood glucose, HbAlc,fasting insulin and HOMA-IR levels were declined greatly after treatment in the treatment group （all P〈0.05）, while the improvement was not obvious （all P〉0.05 ） in the control group. There was significant difference between the two groups （all P〈0.05）. The triglyeerides （TG）, low density lipoprotein-eholesterol （LDL-CH） and total cholesterol （T-ehol）were significantly declined in the treatment group （all P〈0.01 ）. Conclusion Pioglitazone can reduce the insulin level of T2DM patients, and ameliorate insulin resistance, glycol metabolism and the disturbance of lipid metabolism.